John J. Engemann

5.5k total citations · 1 hit paper
23 papers, 2.5k citations indexed

About

John J. Engemann is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, John J. Engemann has authored 23 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 11 papers in Epidemiology and 7 papers in Clinical Biochemistry. Recurrent topics in John J. Engemann's work include Antimicrobial Resistance in Staphylococcus (10 papers), Bacterial Identification and Susceptibility Testing (7 papers) and Infective Endocarditis Diagnosis and Management (6 papers). John J. Engemann is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (10 papers), Bacterial Identification and Susceptibility Testing (7 papers) and Infective Endocarditis Diagnosis and Management (6 papers). John J. Engemann collaborates with scholars based in United States and Argentina. John J. Engemann's co-authors include Keith S. Kaye, Vance G. Fowler, Daniel J. Sexton, Yehuda Carmeli, Sara E. Cosgrove, Jane Briggs, Melissa Bronstein, Vivian H. Chu, G. Ralph Corey and L. Barth Reller and has published in prestigious journals such as Circulation, American Journal of Respiratory and Critical Care Medicine and Clinical Infectious Diseases.

In The Last Decade

John J. Engemann

23 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients withStaphylococcus aureusSurgical Site Infection

2003 723 citations John J. Engemann, Yehuda Carmeli et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by John J. Engemann

Since Specialization

Citations

This map shows the geographic impact of John J. Engemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Engemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Engemann more than expected).

Fields of papers citing papers by John J. Engemann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Engemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Engemann. The network helps show where John J. Engemann may publish in the future.

Co-authorship network of co-authors of John J. Engemann

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Engemann. A scholar is included among the top collaborators of John J. Engemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Engemann. John J. Engemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beyond Infection: Mortality and End-of-Life Care Associated With Infectious Disease Consultation in an Academic Health System 2024 ·Clinical Infectious Diseases ·Alison Smith, (unknown), Arthur W. Baker, Gary M. Cox, Kristen V. Dicks, John J. Engemann, (unknown), Ahmad Mourad, (unknown), Wil L. Santivasi, Nicholas Turner, Rebekah Wrenn, (unknown), Jason E. Stout	1
2	In pursuit of the holy grail: Improving C. difficile testing appropriateness with iterative electronic health record clinical decision support and targeted test restriction 2021 ·Infection Control and Hospital Epidemiology ·Norah S. Karlovich, (unknown), B. Herold Griffith, (unknown), (unknown), John J. Engemann, Jessica Seidelman, Nicholas Turner, Christopher R. Polage, Becky Smith, Sarah S. Lewis	7
3	Social Disadvantage, Politics, and Severe Acute Respiratory Syndrome Coronavirus 2 Trends: A County-level Analysis of United States Data 2020 ·Clinical Infectious Diseases ·Ahmad Mourad, Nicholas Turner, Arthur W. Baker, Nwora Lance Okeke, Shanti Narayanasamy, Robert Rolfe, John J. Engemann, Gary M. Cox, Jason E. Stout	9
4	Therapeutic Drug Monitoring of Antimycobacterial Drugs in Patients with Both Tuberculosis and Advanced Human Immunodeficiency Virus Infection 2009 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·David P. Holland, Carol Hamilton, Amy Weintrob, John J. Engemann, (unknown), Charles A. Peloquin, Jason E. Stout	41
5	Mortality and time to extubation in severe hospital-acquired pneumonia 2008 ·American Journal of Infection Control ·Sarah Connelly, Joanne Trinh, Melissa D. Johnson, Elizabeth Dodds‐Ashley, Jason E. Stout, John J. Engemann, N. Deborah Friedman, Donald Kaye, Keith S. Kaye	7
6	Assessment of Clostridium difficile–Associated Disease Surveillance Definitions, North Carolina, 2005 2008 ·Infection Control and Hospital Epidemiology ·Preeta K. Kutty, Stephen R. Benoit, Christopher W. Woods, Arlene C. Seña, Susanna Naggie, (unknown), John J. Engemann, Sharon Evans, Brian C. Pien, Shailendra N. Banerjee, (unknown), L. Clifford McDonald	40
7	Early Surgery in Patients with Infective Endocarditis: A Propensity Score Analysis 2007 ·Clinical Infectious Diseases ·Olcay Aksoy, Daniel J. Sexton, Andrew Wang, Paul Pappas, Wissam M. Kourany, Vivian H. Chu, Vance G. Fowler, Christopher W. Woods, John J. Engemann, G. Ralph Corey, Tina Harding, Christopher H. Cabell	144
8	Methicillin-Resistant Staphylococcus aureus Outbreak in an Intensive Care Nursery: Potential for Interinstitutional Spread 2007 ·The Pediatric Infectious Disease Journal ·Jay R. McDonald, (unknown), Brian C. Pien, Joanne Trinh, John J. Engemann, Lizzie J. Harrell, (unknown), David Tanaka, Ronald N. Goldberg, Daniel J. Sexton, Keith S. Kaye	20
9	Favorable Impact of an Infection Control Network on Nosocomial Infection Rates in Community Hospitals 2006 ·Infection Control and Hospital Epidemiology ·Keith S. Kaye, John J. Engemann, (unknown), (unknown), (unknown), Daniel J. Sexton	41
10	Use of Vancomycin or First-Generation Cephalosporins for the Treatment of Hemodialysis-Dependent Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia 2006 ·Clinical Infectious Diseases ·Martín E. Stryjewski, Lynda A. Szczech, Danny Benjamin, Jula K. Inrig, Zeina A. Kanafani, John J. Engemann, Vivian H. Chu, Maria Joyce, L. Barth Reller, G. Ralph Corey, Vance G. Fowler	275
11	Relationship between Clinical Outcomes and Vascular Access Type among Hemodialysis Patients with Staphylococcus aureus Bacteremia 2006 ·Clinical Journal of the American Society of Nephrology ·Jula K. Inrig, Shelby D. Reed, Lynda A. Szczech, John J. Engemann, Joëlle Y. Friedman, G. Ralph Corey, Kevin A. Schulman, L. Barth Reller, Vance G. Fowler	44
12	Clinical Outcomes and Costs Due toStaphylococcus aureusBacteremia Among Patients Receiving Long-Term Hemodialysis 2005 ·Infection Control and Hospital Epidemiology ·John J. Engemann, Joëlle Y. Friedman, Shelby D. Reed, Robert I. Griffiths, Lynda A. Szczech, Keith S. Kaye, Martín E. Stryjewski, L. Barth Reller, Kevin A. Schulman, G. Ralph Corey, Vance G. Fowler	123
13	Costs and Outcomes Among Hemodialysis-Dependent Patients With Methicillin-Resistant or Methicillin-SusceptibleStaphylococcus aureusBacteremia 2005 ·Infection Control and Hospital Epidemiology ·Shelby D. Reed, Joëlle Y. Friedman, John J. Engemann, Robert I. Griffiths, Kevin J. Anstrom, Keith S. Kaye, Martín E. Stryjewski, Lynda A. Szczech, L. Barth Reller, G. Ralph Corey, Kevin A. Schulman, Vance G. Fowler	168
14	Surgical-Site Infection Due to Staphylococcus aureus Among Elderly Patients Mortality, Duration of Hospitalization, and Cost 2004 ·Infection Control and Hospital Epidemiology ·Sarah McGarry, John J. Engemann, Kenneth E. Schmader, Daniel J. Sexton, Keith S. Kaye	128
15	Risk Factors for Postoperative Mediastinitis Due to Methicillin-Resistant Staphylococcus aureus 2004 ·Clinical Infectious Diseases ·Elizabeth S. Dodds Ashley, (unknown), John J. Engemann, Anthony Harris, Vance G. Fowler, Daniel J. Sexton, Keith S. Kaye	61
16	Pathogens resistant to antimicrobial agents: Epidemiology, molecular mechanisms, and clinical management 2004 ·Infectious Disease Clinics of North America ·Keith S. Kaye, John J. Engemann, Henry Fraimow, Elías Abrutyn	117
17	Control of Nosocomial Acquisition of Vancomycin-Resistant Enterococcus Through Active Surveillance of Hemodialysis Patients 2004 ·Infection Control and Hospital Epidemiology ·R. Neal Axon, John J. Engemann, James Butcher, (unknown), Keith S. Kaye	12
18	Reference Group Choice and Antibiotic Resistance Outcomes 2004 ·Emerging infectious diseases ·Keith S. Kaye, John J. Engemann, Essy Mozaffari, Yehuda Carmeli	78
19	Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients withStaphylococcus aureusSurgical Site Infection breakdown → 2003 ·Clinical Infectious Diseases ·John J. Engemann, Yehuda Carmeli, Sara E. Cosgrove, Vance G. Fowler, Melissa Bronstein, (unknown), Jane Briggs, Daniel J. Sexton, Keith S. Kaye	723
20	Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis 2003 ·American Journal of Respiratory and Critical Care Medicine ·Jason E. Stout, John J. Engemann, Allen Cheng, (unknown), Carol Hamilton	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact